Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Venus Medtech (Hangzhou) Dividends per Share Related Terms
Venus Medtech (Hangzhou) Dividends per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Venus Medtech (Hangzhou) Dividends per Share Chart
VMTHF vs ABT, SYK, MDT: Dividends per Share Comparison
For the Medical Devices subindustry, Venus Medtech (Hangzhou)'s Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Venus Medtech (Hangzhou) Dividend Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Venus Medtech (Hangzhou)'s Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Venus Medtech (Hangzhou)'s Dividend Yield % falls into.
Venus Medtech (Hangzhou) (VMTHF) has a Dividends per Share of $0.00 as of Dec. 2025. Dividends per share represents the per-share amount paid as dividends. View historical data on Venus Medtech (Hangzhou) and its competitors.
Is Venus Medtech (Hangzhou)'s Dividends per Share too high?
Venus Medtech (Hangzhou)'s current Dividends per Share is $0.00. Overall, Venus Medtech (Hangzhou) has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Venus Medtech (Hangzhou)'s Dividends per Share compare to ABT and SYK?
Venus Medtech (Hangzhou)'s Dividends per Share of $0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends per Share for a Medical Devices & Instruments company?
A good Dividends per Share depends on the Medical Devices & Instruments industry context. However, Dividends per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends per Share mean?
A high Dividends per Share can signal that a stock is expensive relative to its fundamentals. Dividends per share represents the per-share amount paid as dividends. View historical data on Venus Medtech (Hangzhou) and its competitors. Venus Medtech (Hangzhou)'s current Dividends per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Medtech (Hangzhou) stock overvalued right now?
Venus Medtech (Hangzhou) (VMTHF) has a current Dividends per Share of $0.00. The stock's GF Value™ is $1.27, compared to a current price of $0.42 — trading 66.8% below its estimated fair value. The current Dividends per Share is $0.00. Venus Medtech (Hangzhou)'s overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends per Share calculated?
Dividends per Share is calculated from a company's financial statements. For Venus Medtech (Hangzhou) (VMTHF), the current Dividends per Share is $0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Venus Medtech (Hangzhou) (VMTHF) Overvalued in 2026?
Based on GuruFocus' analysis, Venus Medtech (Hangzhou) stock appears to be undervalued.
The current stock price of $0.42 is trading 66.8% below its estimated GF Value™ of $1.27.
Key valuation signals for VMTHF:
Dividends per Share: $0.00
GF Value™: $1.27 vs. price of $0.42 (66.8% below fair value)
No single metric tells the full story. See the VMTHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Venus Medtech (Hangzhou) Inc is engaged in the medical devices that integrate R&D, clinical development, manufacturing, and commercialization. The company has developed a product portfolio covering the interventional devices for valvular heart diseases, including transcatheter aortic valve replacement (TAVR), transcatheter pulmonary valve replacement (TPVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), and other procedural accessories, allowing it to provide overall solutions for physicians and patients. Geographically, the company operates in mainland China, Israel, Hong Kong, the USA, and the Netherlands. The majority of the revenue is derived from Mainland China.
52GF Score
Get the complete analysis for VMTHF
Dividends per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VMTHF has been successfully added to your 
